Cabergoline Before or After Oocyte Collection for Follicular Resolution

Inclusion criteria

• Adult female at least 18 years of age intending to undergo ovarian stimulation for a cycle of IVF.
• Ability read and understand English sufficiently to obtain informed consent and complete a study diary.
• Pre-implantation genetic screening (PGS) is allowed.
• Egg donors are allowed.
• Patients using a gestational carrier are allowed.
• Patients with prior IVF cycles are allowed, but no patient can undergo more than one cycle with oocyte collection under this study.

Exclusion criteria

• Egg banking, donor egg banking, or any cycle type that would preclude immediate culture to blastocyst stage.
• Patients that would be unavailable for the follow-up ultrasound 5 days post-retrieval, such as patients that live far from the clinic (e.g. out of state).
• Uncontrolled hypertension.
• Ergot alkaloid hypersensitivity or allergy.
• History of pulmonary, pericardial, retroperitoneal fibrotic disorders.
• History of bipolar disorder, schizophrenia, or psychotic illness.
• Breast feeding.
• History of eclampsia or pre-eclampsia.
• Severe hepatic dysfunction.
• Current use of any dopamine receptor agonist or antagonist for any purpose, including, but not limited to, cabergoline (Dostinex), aripiprazole (Abilify), bromocriptine (Parlodel), methylphenidate (Ritalin), buproprion (Wellbutrin, Zyban), lisdexamfetamine (Vyvanse).
• Any condition that, in the opinion of the physician or principal investigator, would place the patient at undue risk under this protocol or would otherwise make the protocol inappropriate for that subject.